key: cord-0776149-rpszzjl6
authors: Zhou, Yunjiao; Liu, Zezhong; Li, Shibo; Xu, Wei; Zhang, Qianqian; Silva, Israel T.; Li, Cheng; Wu, Yanling; Jiang, Qingling; Liu, Zhenmi; Wang, Qiujing; Guo, Yu; Wu, Jianbo; Gu, Chengjian; Cai, Xia; Qu, Di; Mayer, Christian T.; Wang, Xiangxi; Jiang, Shibo; Ying, Tianlei; Yuan, Zhenghong; Xie, Youhua; Wen, Yumei; Lu, Lu; Wang, Qiao
title: Enhancement versus Neutralization by SARS-CoV-2 Antibodies from A Convalescent Donor Associates with Distinct Epitopes on the Receptor-Binding Domain
date: 2021-01-12
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.108699
sha: b6028d5df746750596ad4a5935606233e3031554
doc_id: 776149
cord_uid: rpszzjl6

Several potent neutralizing antibodies against SARS-CoV-2 virus have been identified. However, antibody-dependent enhancement (ADE) has not been comprehensively studied for SARS-CoV-2, and the relationship between enhancing versus neutralizing activities and antibody epitopes remains unknown. Here, we select a convalescent individual with potent IgG neutralizing activity and characterize his antibody response. Monoclonal antibodies isolated from memory B cells target four groups of five non-overlapping receptor-binding domain (RBD) epitopes. Antibodies to one group of these RBD epitopes mediate ADE of entry in Raji cells via an Fcγ receptor-dependent mechanism. In contrast, antibodies targeting two other distinct epitope groups neutralize SARS-CoV-2 without ADE, while antibodies against the fourth epitope group are poorly neutralizing. One antibody, XG014, potently cross-neutralizes SARS-CoV-2 variants as well as SARS-CoV-1 with respective IC50 values as low as 5.1 ng/ml and 23.7 ng/ml, while not exhibiting ADE. Therefore, neutralization and ADE of human SARS-CoV-2 antibodies correlate with non-overlapping RBD epitopes.

The ongoing coronavirus disease of 2019 global pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; also known as 2019-nCoV or HCoV-19) (Coronaviridae Study Group of the International Committee on Taxonomy of, 2020; Jiang et al., 2020a; Jiang et al., 2020c) . The four main genera of coronaviruses are known as α, β, γ, and δ. SARS-CoV-2, together with SARS-CoV-1 identified in 2003 and Middle East respiratory syndrome coronavirus (MERS-CoV) identified in 2012, belong to β-CoV genus (Coronaviridae Study Group of the International Committee on Taxonomy of, 2020; Zhou et al., 2020; Zhu et al., 2020) .

For each coronavirus particle, the viral genome is packed with nucleocapsid (N) proteins and surrounded by an envelope containing structural proteins. One of these structural proteins (spike protein; S-protein) trimerizes and mediates viral entry into host cells (Li, 2016) , and it is the major target for human neutralizing antibodies Premkumar et al., 2020; Wu, F. et al., 2020) . It contains 1273 amino acids with a large ectodomain (S-ECD), one transmembrane helix and a small intracellular C-terminus ( Figure S1A ). Two major domains within S-ECD have been identified as S1 head and S2 stalk regions, and the crucial receptorbinding domain (RBD) localizes to the S1 portion ( Figure S1A ).

Since binding of SARS-CoV-2 RBD to its human receptor, angiotensin-converting enzyme-2 (ACE2), is a critical initial step for virus entry into target cells, blocking J o u r n a l P r e -p r o o f this interaction with antibodies is likely a promising approach for both treatment and protection. This would be especially true for broadly neutralizing antibodies targeting conserved epitopes present in different coronaviruses, such as SARS-CoV-1 and the newly emerging SARS-CoV-2, both of which are from the same coronavirus subfamily and share the same human receptor ACE2.

Efforts to obtain human neutralizing antibodies against the S-protein have involved a variety of methods as phage display Sun et al., 2020; Wu, Y. et al., 2020a) , humanized mice (Hansen et al., 2020) , antibody screening from SARS-CoV-1 recovered individuals (Pinto et al., 2020; Wec et al., 2020) , and single B cell antibody cloning from SARS-CoV-2 convalescent donors (Andreano et al., 2020; Brouwer et al., 2020; Cao et al., 2020; Chen et al., 2020; Chi et al., 2020; Ju et al., 2020; Kreer et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Wan et al., 2020; Wu, Y. et al., 2020b; Zost et al., 2020a; Zost et al., 2020b) . The neutralizing activities of these cloned antibodies are radically different, with 50% inhibitory concentration (IC50) values ranging from single digit ng/ml to non-neutralizing. The antibodies that bind to RBD showed generally higher neutralization potency compared with antibodies with non-RBD epitopes (Rogers et al., 2020) . Although some of the reported antibodies showed cross-neutralizing activity Pinto et al., 2020; Wec et al., 2020) , their potency against SARS-CoV-1 and SARS-CoV-2 was not equally high. Moreover, to the best of our knowledge, the antibody-dependent enhancement (ADE) effect of these antibodies J o u r n a l P r e -p r o o f has never been evaluated and, accordingly, the relationship between ADE and different SARS-CoV-2 S-protein epitopes has not been determined.

Antibody-bound virus particles could be attached on the surface of immune cells through Fcγ receptor-mediated internalization for subsequent degradation.

However, instead of protection, antibody binding might facilitate viral particles to enter and invade host cells. This "ADE of viral entry" phenomenon has been documented for many viruses, including Dengue, Zika and SARS-CoV-1 viruses (Eroshenko et al., 2020; Iwasaki and Yang, 2020; Katzelnick et al., 2017; Miner and Diamond, 2017; Salje et al., 2018) . In SARS-CoV-1 infection, antibodies binding the S-protein facilitate ACE2-independent virus internalization into macrophages, monocytes and B cells in vitro (Jaume et al., 2011; Wang et al., 2014; Yip et al., 2014) .

Nevertheless, viral uptake does not necessarily result in a productive viral infection, meaning that ADE of viral entry in vitro does not predict ADE of infection and ADE of disease (Arvin et al., 2020; Halstead and Katzelnick, 2020) . For example, viral replication was abortive in vitro despite enhancement of SARS-CoV-1 virus entry into a B cell line, Raji cells (Jaume et al., 2011) . Whether antibodies against SARS-CoV-2 could induce ADE of viral entry, and whether the invaded viruses undergo active replication, are both still unknown.

Here, we selected a convalescent individual with a high level of serum IgG neutralizing activity against SARS-CoV-2 and isolated many expanded clones of memory B cells expressing closely related antibodies with the same Ig variable gene J o u r n a l P r e -p r o o f segments and highly similar CDR3 sequences. Most of these isolated antibodies targeted four groups of five distinct epitopes on the RBD of S-Protein.

Characterization of both neutralizing and enhancing activities of these antibodies identified an RBD-binding antibody which potently neutralized both SARS-CoV-1 and SARS-CoV-2 and do so without promoting ADE of viral entry. Interestingly, antibodies to one group of RBD epitopes were significantly associated with ADE of entry, while also exhibiting various degrees of neutralization.

Serum samples were collected from 16 donors, who had recovered from SARS-CoV-2 infection, and from eight donors before the COVID-19 outbreak ( Figure S1B ).

Compared with the unexposed donors, the sera from recovered individuals displayed significantly higher binding to the SARS-CoV-2 S-protein domains (RBD, S1, S2 and S-ECD) by ELISA ( Figure 1A -1D; Figure S1A ). The N-protein within the virion also elicited a robust antibody response after infection ( Figure 1E ). To determine the neutralizing activity in convalescent sera, we tested their ability to block infection by luciferase-expressing SARS-CoV-2 or SARS-CoV-1 pseudovirus in Huh-7 cells Xia et al., 2020b) . The luciferase signal, a surrogate of infection, in the presence of sera or purified IgG antibodies was then compared across a wide range of dilutions ( Figure 1F -1H). Although five individuals (donor #5, #6, #7, #8 and #16) reached half-maximal neutralizing titers (NT50) above 2000 for J o u r n a l P r e -p r o o f serum samples ( Figure 1F ), only one individual (donor #16) showed potent neutralization for the purified IgG fraction (NT50: 1.1 μg/ml; Figure 1H ). This discrepancy was possibly due to the neutralizing activities of IgM or IgA antibodies in those convalescent individuals. The serum neutralizing activities of convalescent individuals were much lower against SARS-CoV-1 pseudovirus, yet slightly higher than those in the naïve donors ( Figure 1G ). Thus, all 16 convalescent donors mounted robust antibody responses against SARS-CoV-2 S-protein by ELISA, while five donors showed high levels of serum neutralizing activities, out of which we selected one for further studies owing to its exceptional serum IgG neutralizing activity.

To determine which domain on the S-protein is the dominant target of the neutralizing IgG response in this selected top neutralizer (donor #16), we used RBD, S1, S2 and S-ECD proteins, respectively, to block neutralization in vitro. As shown, the IgG neutralizing activity could be partially blocked by RBD, S1 and S-ECD domains, respectively, but not by the S2 domain ( Figure 1I ). These results suggest that the neutralizing antibody response in donor #16 is directed primarily against the S1 domain and, more specifically, against the RBD within that protein.

To characterize the IgG antibodies responsible for the potent neutralizing activity in this selected individual, we identified SARS-CoV-2 RBD-or S-ECD-binding B cells using a dual-dye labeling strategy ( Figure S2A ) . The J o u r n a l P r e -p r o o f unexposed naïve control showed background levels of bait protein-specific B cells, while donor #16 with high serum neutralizing activity displayed a distinct population of bait protein-binding B cells (Figure 2A-2C ). Avi-tagged biotinylated RBD, chemically biotinylated S-ECD and Avi-tagged biotinylated S-ECD bait proteins stained B cells at a frequency of 0.025%, 0.12% and 0.21%, respectively, which were about 6-to 20-fold over that of background staining (Figure 2A-2C ).

The gated double positive cells (bait protein-PE + and bait protein-APC + ) were single cell-sorted, and immunoglobulin heavy (IGH; IgG isotype) and light (IGL or IGK) chain genes were amplified by nested PCR (Robbiani et al., 2017; Scheid et al., 2009; Wang, Q. et al., 2020) . Overall, we obtained 292 paired heavy and light chain variable regions from RBD-binding and S-ECD-binding IgG + memory B cells ( Figure   2D ; Table S1 ). Sequence analysis showed a broad spectrum of immunoglobulin heavy chain V gene (IGHV) usage, CDRH3 amino acid length distribution and mutation frequency ( Figure S2B -S2D). Moreover, 25 expanded clones producing antibodies encoded by the same Ig variable gene segments with closely related CDR3 sequences were identified ( Figure 2D ; Table S1 ). The antibodies from the same clones showed 80% or higher similarities at the amino acid level ( Figure S2E ).

We conclude that this SARS-CoV-2 neutralizer, similar to other reported donors Kreer et al., 2020; Robbiani et al., 2020) , produced clones of antigen-binding memory B cells that express related Ig heavy and light chains.

In total 48 antibodies, designated as XG001 to XG048, were selected for expression and further characterization: 28 from 25 expanded clones and 20 from singlets ( Figure 2D ; Table S1 ). 45 out of 48 antibodies (94%) showed reactivity to the SARS-CoV-2 S-ECD protein (non-binders: gray name; Figure 3A ), and 23 out of 48 (48%) antibodies showed RBD binding capacity (red name, Figure 3B ). All of these RBDbinding antibodies showed ELISA binding against the S1 domain, as expected ( Figure 3B and 3C ). An additional 11 antibodies with no RBD-binding (23%) also bound to the S1 domain (blue name, Figure 3C ), suggesting reactivity to the Nterminal domain (NTD), as previously reported (Chi et al., 2020) . We also found five out of 48 antibodies (10%) that bound to the S2 domain (green name, Figure 3D ).

Moreover, six of 48 antibodies (12%) with no or only weak binding to S1/S2/RBD proteins showed S-ECD binding affinity (purple name, Figure 3A -3D), implying that these antibodies recognize epitopes not present or altered in separate domains. In summary, the selected 48 antibodies from this volunteer recognize various epitopes on the SARS-CoV-2 S-protein, and almost half of them bind to the RBD ( Figure 3E ).

To further determine whether the RBD-binding antibodies bind to overlapping or non-overlapping epitopes, we performed competition ELISAs. Antibodies with weak levels of ELISA binding (XG010, XG015, XG042, XG045, XG047) were excluded. The coated RBD protein was first pre-incubated with a non-biotinylated first antibody followed by incubation with a second biotinylated antibody. As expected, all of the tested antibodies competed with themselves (yellow rectangles, Figure 3F ), while control antibody anti-HBs H004 failed to block any of the RBD J o u r n a l P r e -p r o o f antibodies ( Figure 3F ). In the RBD (amino acid 330-530), four mutually exclusive groups of antibodies (Group-I, II, III and IV) were identified by the competition ELISAs (red rectangles, Figure 3F ). Further competition ELISA assays showed that the epitope of monoclonal antibody CR3022 (ter Meulen et al., 2006) overlapped with Group-I and -II, but not -III and IV, antibodies ( Figure 3F ). Moreover, the binding of ACE2 was efficiently blocked by all the tested antibodies ( Figure 3F ), except three monoclonals, CR3022, consistent with a previous report (Tian et al., 2020) , a non-neutralizing antibody XG026, and a potently neutralizing antibody XG014.

In Group-III, although antibodies XG017 and XG022 blocked the binding of XG008 and XG038, the latter two antibodies bound non-competitively to RBD (two orange boxes, Figure 3F ). Thus, among Group-III antibodies, we had found two mutually exclusive sub-epitopes. This was further confirmed by showing that a combination of four antibodies recognizing distinct epitopes could not block the binding of the fifth antibody to either RBD or S-ECD proteins ( Figure S3A -S3C). Moreover, antibodies in each RBD group have different IGHV and IGKV/IGLV usage ( Figure   S3D ). Besides the four groups of non-overlapping antibodies against SARS-CoV-2 RBD, two antibodies, XG009 and XG043, competed across groups ( Figure 3F ), which could be interpreted by their binding mode bridging all these epitopes or by altered antigen conformation induced by antibody binding. Together, these results indicate that there are at least four groups comprising five non-overlapping antibody binding epitopes on the RBD of SARS-CoV-2.

J o u r n a l P r e -p r o o f

To determine whether our selected antibodies block SARS-CoV-2 infection in vitro, we performed neutralization assays using luciferase-expressing SARS-CoV-2 pseudoviruses to infect Huh-7 cells Xia et al., 2020b) and calculated their IC50 values ( Figure 4A and 4B). The neutralizing activity of these antibodies varied dramatically, ranging from potent neutralizers to non-neutralizing.

Among the 48 tested antibodies, almost half of them (23 antibodies) showed neutralizing activities with IC50 values lower than 10 μg/ml, while seven of them were the most potent with IC50 values lower than 0.1 μg/ml ( Figure 4C ). These neutralizing antibodies recognized distinct epitopes, including RBD, S2, or other non-RBD domains. Similar to other studies (Premkumar et al., 2020; Rogers et al., 2020) , most of our cloned monoclonals with neutralizing activity bound S-protein RBD ( Figure 4C ). The most potent antibodies displayed IC50 values of 6-15 ng/ml, with four of them being RBD-binding, including XG005 (IC50: 6.1 ng/ml), XG014 (IC50:

14.4 ng/ml), XG016 (IC50: 9.1 ng/ml) and XG038 (IC50: 12.7 ng/ml), and one of them being S1-binding but not RBD-binding, namely, XG027 (IC50: 15.7 ng/ml) ( Figure 4A and 4B).

We then chose several monoclonals (XG005, XG008, XG013, XG014, XG016, XG017) to confirm their neutralizing activities using authentic SARS-CoV-2 virus (Figure 4D-4F; Figure S4 ). Infectivity was quantified using immunofluorescence by anti-Nprotein polyclonal antibodies ( Figure 4D ; Figure S4 ) as well as quantitative reverse J o u r n a l P r e -p r o o f transcription PCR of the culture medium ( Figure 4E ). Results were consistent across these two readouts and showed that these antibodies were potent neutralizers against authentic SARS-CoV-2 viruses, with IC50 values as low as single digit ng/ml, such as XG014 (IC50: 5.1 ng/ml) ( Figure 4E and 4F). Compared with SARS-CoV-2 pseudovirus, some monoclonals, such as XG017, showed significantly more neutralizing activities against authentic SARS-CoV-2 viruses, while others, including XG005 and XG016 had reduced effects ( Figure 4B and 4F). We conclude that several isolated monoclonal antibodies, such as RBD-binding antibodies XG014 and XG017, could potently neutralize authentic SARS-CoV-2 virus in vitro.

To determine the relationship between the neutralizing activity of monoclonals and their binding epitopes, we performed unsupervised hierarchical clustering using the nine normalized luciferase values from neutralization assays with their corresponding epitope labelled ( Figure 4G ). Antibody clusters A-D with different levels of neutralizing activity were identified. Compared with non-neutralizing antibodies in Cluster-D, antibodies in Cluster-A and -B, most of which are against RBD Group-II, -III, and -IV epitopes, were potent neutralizers, while antibodies in Cluster-C were weakly neutralizing antibodies ( Figure 4G ). Antibodies targeting the RBD Group-I epitope were barely neutralizing in our assays ( Figure 4G ). Therefore, potent neutralizing antibodies target some, but not all RBD epitopes.

J o u r n a l P r e -p r o o f Point mutations in MERS-CoV and SARS-CoV-1 have been demonstrated to confer resistance to naturally occurring neutralizing antibodies (Sui et al., 2008; Tang et al., 2014; ter Meulen et al., 2006) . The pandemic SARS-CoV-2 virus is also slowly mutating (Korber et al., 2020; Li et al., 2020) . Thus, monitoring the single amino acid changes and understanding their underlying phenotypical relevance are crucial. To extract more structural information about the location of antibody epitopes and to assess antibody responses against escape mutations, we performed ELISA assays using 32 RBD mutants, including 25 naturally occurring mutants and 7 alanine mutants (F377A, S383A, P384A, T385A, K386A, L390A and D428A) ( Figure 5A ).

Comparing with the binding to wild-type RBD, Group-I and -IV, but not -II and -III, antibodies showed reduced binding activity to RBD mutant L390A ( Figure 5A and 5B). Neutralizing antibodies XG022, XG017, XG008, XG014, XG005, and XG025 exhibited resistance to most mutations ( Figure 5A ).

To test the possibility that some of these mutations might be acquired in order to confer antibody resistance we picked two monoclonals, XG014 and XG038, for neutralization assays against several SARS-CoV-2 pseudoviruses carrying some of these reported RBD mutations, such as V341I, F342L, V367F, R408I, A435S, G476S, and V483A ( Figure 5B ). All SARS-CoV-2 variants tested remained sensitive to XG014 ( Figure 5C ), while two out of the seven viruses showed resistance to XG038 antibody neutralization (G476S and V483A; Figure 5D ). This result is consistent with the ELISA result that XG038 exhibited reduced binding activity to these two J o u r n a l P r e -p r o o f RBD mutants (G476S and V483A; Figure 5A ). Therefore, some RBD point mutations can confer SARS-CoV-2 resistance to some human neutralizing antibodies.

To further determine the breadth of our cloned monoclonal antibodies, we measured their neutralizing activity against SARS-CoV-1 pseudoviruses in vitro.

XG014 and XG041 could neutralize SARS-CoV-1 pseudovirus in vitro, with IC50 values of 23.7 ng/ml and 1140 ng/ml, respectively (Figure 5E and 5F; Figure S5 ).

None of the other antibodies showed neutralizing activity against SARS-CoV-1 pseudovirus in our assays ( Figure 5E ). Thus, SARS-CoV-2 infection can generate rare cross-neutralizing antibodies, such as XG014, which potently neutralize SARS-CoV-1 and SARS-CoV-2, as well as SARS-CoV-2 RBD mutants.

Although antibodies can clear viruses or infected cells through its binding to Fcγ receptors on host immune cells, these interactions could also lead to disease enhancement during coronavirus infection (Eroshenko et al., 2020; Iwasaki and Yang, 2020) . Determination of ADE effect would be a crucial step for the clinical use Figure   6A ; Figure S6B ). Among the 11 enhancing antibodies, nine were RBD-binding antibodies, and two antibodies bound to S1, but not RBD ( Figure Figure   S6C ) were calculated as previously reported (Bardina et al., 2017; 2019)( Figure 6C ; Figure S6D ), and a positive correlation was observed between these two values ( Figure S6E ). However, no significant correlation was observed between the calculated IC50 values of neutralization and the corresponding ADE AUC or enhancing power values ( Figure S6F and S6G).

Antibody-dependent viral entry was fully abrogated by GRLR mutations G236R and L328R (Horton et al., 2008) in the antibody Fc receptor-binding site ( Figure 6D and 6E). A similar effect was also achieved by incubating the cells with anti-FcγRII J o u r n a l P r e -p r o o f antibodies ( Figure 6F ), further demonstrating the requirement of Fcγ receptor binding for antibody-dependent SARS-CoV-2 viral entry. Therefore, some SARS-CoV-2 anti-RBD and anti-S1 antibodies induce ADE of viral entry in Raji cells through Fcγ receptor-dependent mechanism.

To examine whether such ADE effect could also be seen with authentic SARS-CoV-2 virus, we infected Raji cells with authentic SARS-CoV-2 virus in the presence of different monoclonals. Similar to PBS, only the background level of viral RNA was detected in the presence of non-ADE antibody XG038 ( Figure 6G ). ADE antibodies, XG005 and XG016, induced higher levels of cellular viral load, especially after 24 hours of incubation ( Figure 6G ), suggesting that the ADE of viral entry by authentic SARS-CoV-2 virus in immune cells is similar to that observed with pseudovirus.

Moreover, the low level of viral RNA detected in the cells after 6 hours incubation suggested that a longer period of incubation is required for antibody-mediated viral entry in vitro ( Figure 6G ). However, compared with those after 24 hours incubation, a decreased level of viral RNA after 48 hours incubation ( Figure 6G ) is similar to the abortive SARS-CoV-1 infection previously reported (Jaume et al., 2011) . Taken together, despite the ability of SARS-CoV-2 virus for ADE of viral entry, no significant viral replication was detected in Raji cells.

J o u r n a l P r e -p r o o f Clinically, it would be imperative to segregate antibodies based on a combination of functional features. Accordingly, we performed unsupervised hierarchical clustering using the nine normalized luciferase values from both neutralization assays and the ADE assays. Three major antibody clusters (Cluster-X, -Y and -Z) were identified ( Figure 7A ). Cluster-X antibodies were characterized by having both neutralizing and enhancing activities. Cluster-Y antibodies displayed potent neutralizing activity, but low levels of antibody-induced viral infection, while antibodies from Cluster-Z were non-neutralizing and did not induce viral entry ( Figure 7A ). Further comparison using ADE AUC and neutralizing IC50 verified that Cluster-X antibodies induced more robust antibody-dependent viral entry in Raji cells ( Figure 7B ), and that the antibodies from Cluster-X and -Y ( Figure 7C ) and from expanded clones ( Figure S7A ) were more potent neutralizers.

To determine any association between antibody properties and their antigen epitopes recognized, we labelled their epitopes on the constructed tree. In Cluster-X, eight out of nine (89%) antibodies interacted with RBD, and all of these eight antibodies, including XG009 and XG043, recognized the RBD Group-IV epitope ( Figure 7A ). This percentage was significantly higher than that in other clusters (p = 0.001 vs. Cluster-Y; p < 0.001 vs. Cluster-Z) ( Figure 7A and 7D). Except for one Group-IV antibody in Cluster-Y, XG014, all other Group-IV antibodies were branched in Cluster-X ( Figure 7A and 7D) and induced a statistically significant level of antibody-dependent viral entry in Raji cells ( Figure 7E ). Unsupervised hierarchical clustering was further performed using only ADE values, which alone were J o u r n a l P r e -p r o o f sufficient to produce an antibody cluster significantly associated with the RBD Group-IV epitopes ( Figure S7B ). Thus, we revealed a significant association between one of the five RBD epitopes, Group-IV, and ADE effects detected in vitro.

We also noticed that some RBD epitopes were associated with only neutralizing activity but no ADE effect. Antibodies in Cluster-Y possessed neutralizing activity, but induced no or low levels of viral entry in Raji cells ( Figure 7A -7C). These antibodies were directed against many distinct epitopes, including RBD Group-II and RBD Group-III epitopes. These antibodies, which recognize only Group-II or only Group-III epitopes, were not found in other clusters but just Cluster-Y ( Figure   7A and 7D), suggesting that antibodies against these epitopes are tightly associated with neutralizing activity and induce no enhancing effects.

Therefore, we conclude that antibodies targeting two RBD epitopes (Group-II and Group-III) neutralize SARS-CoV-2 virus without enhancing activities, while RBD Group-IV antibodies are tightly associated with enhancement of SARS-CoV-2 infection in vitro.

Convalescent plasma shows potential benefits for treating SARS-CoV-2 infection (Duan et al., 2020; Shen et al., 2020) , and many research teams used a single cellbased antibody cloning strategy to identify monoclonal antibodies against SARS-J o u r n a l P r e -p r o o f CoV-2 for potential passive antibody administration as a prevention and treatment.

The same strategy was previously successfully used to identify potent broadly neutralizing antibodies against HIV, ZIKV, HBV, and other pathogens (Robbiani et al., 2017; Walker and Burton, 2018; Wang, Q. et al., 2020) . In the present study, we focused exclusively on one convalescent donor with potent IgG neutralization capacity, cloned and characterized his monoclonal antibodies, and investigated antibody enhancing versus neutralizing effects and their relationship with antigen epitopes.

Serologic neutralizing activity against SARS-CoV-2 varied greatly among recovered individuals (Robbiani et al., 2020; Wu, F. et al., 2020) . Unexpectedly, our result showed that the individuals with a robust serum neutralizing effect did not necessarily have potent neutralizing activity of their purified IgG antibodies ( Figure   1F and 1H). This discrepancy is probably due to the neutralizing effect by non-IgG antibodies, especially by secretory IgA antibody, which plays a significant role in safeguarding mucosal surfaces against respiratory viruses. In COVID-19 patients, an early and robust serum IgA responses was observed (Cervia et al., 2020; Padoan et al., 2020; Yu et al., 2020) and monoclonal IgA antibodies have been tested as effective as IgG by in vitro binding and neutralizing assays (Ejemel et al., 2020; .

Although the ADE effect for coronaviruses has been reported in vitro, a potential pathological relevance during SARS-CoV-2 infection seems unlikely (Arvin et al., J o u r n a l P r e -p r o o f 2020) . Clinical severity of SARS-CoV-2 infection is tightly associated with elders with preexisting conditions but not individuals with previous coronavirus infection (Halstead and Katzelnick, 2020) . Although several monoclonals isolated from convalescent donors exhibited an enhancement of viral entry ( Figure 6A ), our ADE assays using sera from the exactly same convalescent donors showed no ADE of SARS-CoV-2 viral entry ( Figure S6A ), suggesting that the concentration of ADE monoclonals is not sufficiently high among the polyclonal serum. Furthermore, our ADE assay using authentic SARS-CoV-2 virus showed an abortive replication, a phenomenon reminiscent of SARS-CoV-1 (Jaume et al., 2011) . All these data imply the unlikeliness of ADE of infection/disease during SARS-CoV-2 infection. However, there is one exception, feline infectious peritonitis virus (FIPV), which causes ADE of disease in cat (Weiss and Scott, 1981) . This discrepancy with SARS-CoV-1, -2, and MERS-CoV could be explained by the fact that the dominant target of FIPV in vivo is peritoneal macrophages but not pulmonary epithelium.

Our study revealed that 11 out of 48 (23%) monoclonal anti-SARS-CoV-2 IgG antibodies displayed ADE of viral entry in vitro. Although this effect was FcγRIIdependent in Raji cells, ADE of viral entry was not observed in a human erythroleukemic cell line, K562, which is also FcγRII-positive (Zang et al., 2020) , suggesting that FcγRII-expressing is required, but not sufficient, for the antibody- Uptake of viral particles through the ADE pathway might lead to the elevated production of proinflammatory cytokines (Liu et al., 2019) . During SARS-CoV-2 infection, substantially elevated IgG antibody responses (Cao, 2020; and dramatically increased serum levels of proinflammatory cytokines Wang, J. et al., 2020) have been consistently observed in critically ill patients. Patients with severe COVID-19 exhibit elevated levels of proinflammatory cytokines, such as IL-6, IL-1β, and IL-2. Thus, whether ADE of viral entry would lead to high levels of cytokines in B lymphocytes is another question that needs to be addressed using authentic SARS-CoV-2 virus in vitro and in vivo.

Antibodies from our donor bound to five non-overlapping RBD epitopes, similar to other studies reporting three or four distinct antigenic sites within RBD Robbiani et al., 2020; Rogers et al., 2020; Wec et al., 2020; Wu, Y. et al., 2020b; Zost et al., 2020a) . Importantly, we found a significant association of ADE with one of five non-overlapping antibody binding RBD epitopes. This was a surprising result given that no such epitope-ADE relationship has ever been reported for coronaviruses to the best of our knowledge. The underlying mechanism warrants further investigation.

Since SARS-CoV-1 and SARS-CoV-2 share the same human receptor, ACE2, it is possible that antibodies that are cross-reactive to these two different viruses are occasionally generated. A recent study showed that H014, a phage antibody isolated from RBD-immunized mice, showed IC50 of 150 ng/ml and 450 ng/ml for SARS-CoV-1 and -2, respectively . Also, antibodies isolated from individuals with SARS-CoV-1 infection have been shown to be cross-neutralizing for SARS-CoV-2: antibodies ADI-55688 (IC50 of 4 ng/ml and >100 ng/ml for SARS-CoV-1 and -2, respectively), ADI-56046 (IC50 of 20 ng/ml and 50 ng/ml for SARS-CoV-1 and -2, respectively) (Wec et al., 2020) , and S309 (IC50 of 120 ng/ml and 79 ng/ml for SARS-CoV-1 and -2, respectively) (Pinto et al., 2020) . However, whether such crossneutralizing antibodies also develop after SARS-CoV-2 infection is less established.

We here identified a potent neutralizing antibody, XG014, that inhibited infection by both SARS-CoV-2 and SARS-CoV-1 with IC50 values of 5.1 ng/ml and 23.7 ng/ml, respectively. Therefore, XG014 is among the most potent cross-neutralizing antibodies described so far. Importantly, XG014 did not display ADE. This was a surprising finding given that it targets the Group-IV RBD epitope strongly associated with ADE ( Figure 7A ). One possible explanation is that, after viral uptake in the form of immune complexes, the XG014 antibody binding is stable enough at acidic pH within endosomes to prevent endosomal fusion, while other Group-IV antibodies could not withstand the low pH environment. Similar hypothesis has been made for antibodies against flaviviruses (Rey et al., 2018) . Another possible explanation is that the epitope recognized by J o u r n a l P r e -p r o o f XG014 is slightly different from other Group-IV antibodies. Further structural analysis of XG014, compared with those of other Group-IV ADE antibodies, would help us to decipher the correlation between ADE and epitopes in depth.

Supplemental Information includes 7 figures and 1 table.

We would like to thank all the volunteers in this study, especially donor #16 for devoting time to our research. We thank members of the Core Facility of were grouped together and represented as a slice. In total 25 slices were identified, and IGHV and IGKV/IGLV genes are shown for each slice (see more details in Table   S1 ). Antibody singlets are in one big silver slice. In total, 48 monoclonal antibodies J o u r n a l P r e -p r o o f (XG001~XG048) were selected for further characterization. See also Figure S2 and Table S1 . (E) Based on antigen-binding assays, 48 antibodies were categorized into five types.

Red, RBD-binding antibodies. Blue, S1-but not RBD-binding antibodies. Green, S2binding antibodies. Purple, S-ECD-but not RBD/S1/S2-binding antibodies. Gray, no binding on the tested antigens. The names of monoclonals in (A-D) are color-coded correspondingly.

(F) A competition ELISA defines four non-overlapping epitope groups (four symbols with the corresponding red rectangles) and a fifth overlapping epitope group (XG009 and XG043, overlapping with Group-II, III and IV antibodies) of RBD-binding antibodies. The 1 st antibodies/proteins (x-axis) were non-biotinylated and used to block the epitopes, while the 2 nd antibodies/proteins (y-axis) were biotinylated for detection by streptavidin-HRP. Results of competition ELISA are shown as percent of binding by the 2 nd biotinylated antibodies compared to PBS-blocked references, and are illustrated by colors: black, 0%-25%; dark gray, 25%-50%; light gray, 50%-75%; white, >75%. All of the tested antibodies blocked the binding of their own biotinylated versions (yellow rectangles). XG008 and XG038 bind two mutually J o u r n a l P r e -p r o o f exclusive sub-epitopes (orange rectangles) in RBD Group-III. Anti-HBs antibody H004 was used as negative control. Monoclonal antibody CR3022 (ter Meulen et al., 2006) and recombinant ACE2 protein (Wu, Y. et al., 2020a) were used for mapping the epitopes of our cloned antibodies. Weak RBDbinders (XG015, XG042, XG045, XG047) were excluded in this assay. Representative of two experiments. See also Figure S3 . Figure 3E ).

(C) The antigen epitopes of neutralizing antibodies with IC50 lower than 10 or 0.1 μg/ml are summarized in columns.

J o u r n a l P r e -p r o o f (D) Immunofluorescent staining of SARS-CoV-2 N-protein for in vitro neutralization assays against authentic SARS-CoV-2 virus. Immunofluorescence using anti-Nprotein polyclonal antibodies was used to evaluate the neutralizing effect of selected monoclonals. Non-neutralizing antibody XG020 was used as a negative control. Scale bar, 400 µm. Immunofluorescent and DAPI staining figures of other monoclonals are shown in Figure S4 .

(E and F) Quantitative reverse transcription PCR results (E) and the corresponding IC50 values (F) for in vitro neutralization assays against authentic SARS-CoV-2 virus.

SARS-CoV-2 N-protein RNA copy numbers were calculated using a standard curve composed of seven prepared N-protein DNA samples with 10-fold serial dilutions.

At least two independent experiments were performed.

(G) Clustering analysis identified antibody epitopes associated with neutralizing activity. Unsupervised hierarchical clustering was performed using the SARS-CoV-2 pseudovirus neutralization data in the presence of nine dilutions of 45 monoclonals.

Cluster-A, -B, -C, and -D were identified. Antibodies with no ELISA binding against our tested antigens (XG021, XG034, XG039) were excluded. Antibodies with different epitopes on the S-protein or RBD are color-coded or shape-coded, respectively. See also Figure S4 . capacities are shown as percent of binding to wild-type RBD and are illustrated by colors: black, 0%-25%; dark gray, 25%-50%; light gray, 50%-75%; white, >75%.

(B) Structure diagram of SARS-CoV-2 RBD (PDB ID 6W41, crystal structure of SARS-CoV-2 RBD) with several positions of the tested mutations marked. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Qiao Wang (wangqiao@fudan.edu.cn).

All unique reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement. Sharing of antibodies with academic researchers may require a payment to cover the cost of generation and a completed Material Transfer Agreement.

The published article includes all datasets generated or analyzed during this study.

Additional Supplemental Items are available from Mendeley Data at https://data.mendeley.com/datasets/bjpky4bzsd/1.

Volunteer recruitment and blood draws were performed at the Zhoushan Hospital under a protocol approved by the Zhoushan Hospital Research Ethics Committee . Experiments related to all human samples were performed at the J o u r n a l P r e -p r o o f School of Basic Medical Sciences, Fudan University under a protocol approved by the institutional Ethics Committee (2020-C007) . Study participants, 16 convalescent donors, whose infections have been confirmed by PCR, and 8 unexposed naïve donors. All donors ranged in age from 7-67 with a mean of 37, and the female:male ratio was 14:10 ( Figure S1B ).

African green monkey kidney Vero-E6 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heatinactivated fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin. Raji cells (human Burkitt's lymphoma B lymphoblast) (Jaume et al., 2011) , were maintained in RPMI 1640 supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. All cell lines were cultured at 37°C in 5% CO2. Human embryonic kidney 293F (HEK293F) suspension cells were cultured using HEK293 serum-free OPM-293-CD05 medium (OPM Biosciences) at 37°C in 5% CO2 with shaking at 100 rpm.

The authentic SARS-CoV-2 virus, nCoV-SH01 (GenBank: MT121215.1) used in this study was isolated from infected patients at the Biosafety Level 3 (BSL-3) laboratory at the Shanghai Medical College, Fudan University (Wu, Y. et al., 2020a) . The SARS-CoV-2 virus was propagated in Vero-E6 cells. Concentrated virus stock was J o u r n a l P r e -p r o o f aliquoted and stored at liquid nitrogen. One aliquot of cell line-passaged authentic SARS-CoV-2 virus, originally launched from patient serum and stored at -80°C, was thawed for in vitro cell infection experiments.

E. coli Trans5α (TransGen Biotech) were cultured at 37°C with shaking at 230 rpm.

Samples of peripheral blood were collected from SARS-CoV-2 patients at the Zhoushan Hospital in Zhejiang province. Serum samples were heat inactivated for 60 minutes at 56°C, separated by centrifugation of coagulated whole blood, and aliquoted for storage at -80°C. After a 400 ml blood draw from donor #16, human peripheral blood mononuclear cells (PBMCs) were isolated using a cell separation tube with frit barrier. The isolated PBMCs were resuspended in 90% heatinactivated FBS supplemented with 10% dimethylsulfoxide (DMSO) and cryopreserved in liquid nitrogen.

All the cloned human monoclonal antibodies, their GRLR version, and the previously reported monoclonal antibody CR3022 (ter Meulen et al., 2006) were prepared by transient transfection of mammalian HEK293F cells as previously reported (Wu, Y. et al., 2020a) .

The ELISA binding of serum samples or purified IgG antibody fractions from serum samples or recombinant IgG antibodies against SARS-CoV-2 proteins, including S-ECD-, RBD-, S1-, S2-, and N-proteins (see details in KEY RESOURCES TABLE) was measured as previously reported . Briefly, ELISA plates were first coated with 10 μg/ml of antigen in phosphate buffered saline (PBS) overnight at 4°C, and then blocked with 2% bovine serum albumin (BSA) in PBS. The serum or 1 st antibody was serially diluted 1:3 in PBS (maximum concentration, 1:10 for serum, 10 μg/ml for monoclonals) for eight dilutions in total, and added for incubation for one hour at room temperature. Visualization was with HRP-conjugated goat antihuman IgG (Thermo Fisher Scientific) or HRP-conjugated mouse anti-human IgG Fab (GenScript). The area under the curve (AUC) was calculated for each antibody by analysis using PRISM software to evaluate the antigen-binding capacity. ELISA assays using RBD mutants was performed as described above except coating RBD-Fc at a concentration of 2 μg/ml, and using wild-type RBD as a reference for normalization.

Competition ELISAs were performed as described previously .

Briefly, plates were coated with 2 μg/ml SARS-CoV-2 RBD or 2 μg/ml SARS-CoV-2 S-ECD and incubated with 15 μg/ml 1 st blocking antibody/proteins (60 μg/ml for antibody CR3022) for two hours. Biotinylated 2 nd antibodies/proteins (0.25 μg/ml) J o u r n a l P r e -p r o o f (15 μg/ml for antibody CR3022) were directly added for 30 minutes at room temperature. Detection was performed with streptavidin-HRP (BD Biosciences).

PBS buffer substituted for the 1 st blocking antibody was used as a reference for normalization, while the anti-HBs antibody H004 , which could not block the binding of the 2 nd antibodies, served as a negative control.

The pseudotyped viruses were produced as previously reported .

Briefly, plasmids pNL4-3.luc.RE (the luciferase reporter-expressing HIV-1 backbone) and pcDNA3.1-SARS-CoV-1-S/pcDNA3.1-SARS-CoV-2-S (encoding for the S-protein of SARS-CoV-1 or SARS-CoV-2) were co-transfected into HEK293T cells using the transfection reagent VigoFect (Vigorous Biotechnology, Beijing). The supernatant containing the released pseudotyped particles was harvested at 72 hours posttransfection. After centrifugation, the supernatant was collected, aliquoted, and frozen at -80°C. The production of the SARS-CoV-2 pseudovirus mutants was performed as described above except using the plasmids of pcDNA3.1-SARS-CoV-2 with the corresponding mutations (V341I, F342L, V367F, R408I, A435S, G476S, and V483A) in the S-protein (Ou et al., 2020) . These plasmids were constructed using the plasmid of pcDNA3.1-SARS-CoV-2-S as a template by a site-directed mutation kit (Yeasen Biotech, Shanghai).

In vitro SARS-CoV-1 and SARS-CoV-2 pseudovirus infection was performed as previously described . Briefly, 1×10 4 /well Huh-7 cells were seeded in 96-well plates in DMEM supplemented with 10% FBS. The seeded cells were cultured for an additional eight hours before infection. To quantitate the neutralization capacity, the human serum (maximum concentration, 1:20), polyclonal antibodies purified from human serum (maximum concentration, 50 μg/ml), or monoclonal antibodies (maximum concentration, 10 or 1 or 0.625 μg/ml) was serially diluted 1:2 in DMEM medium for nine dilutions in total. Subsequently, the diluted antibodies or serum samples were incubated with SARS-CoV-1 or -2 pseudoviruses for 30 minutes at 37°C before added onto Huh-7 cells for infection.

For the neutralization blocking experiments, different antigens (RBD, S1, S2 or S-ECD proteins) were incubated at different concentrations, respectively, with 5 µg/ml purified IgG from donor #16 for one hour at 37°C before incubation with SARS-CoV-2 pseudovirus. After incubation for half an hour, the mixture was finally added to the Huh-7 cells for infection. After incubation for 12 hours, the supernatant was replaced with fresh DMEM medium supplemented with 2% FBS. The cell supernatant was removed after culture for further 48 hours, and the cells were lysed for luciferase activity measurement using a Firefly Luciferase Assay Kit (Promega) and luminometer according to the manufacturer's instructions.

The absolute luciferase values were measured and the relative values were calculated by normalizing to the virus-only control well in the same lane. For example, the absolute luciferase value in a pseudovirus-only control well J o u r n a l P r e -p r o o f (considered as reference) was 5×10 4 , while adding one neutralizing serum sample might reduce this to 1×10 4 . Therefore, the normalized luciferase values were calculated as 100% in the pseudovirus-only control and 20% for this neutralizing serum. Since many aspects, such as pseudovirus concentration, cultured cell concentration, status of the cells, immunofluorescence reading, and etc., varied dramatically between different plates and different tests, normalization is necessary for combining data for comparison. For the serum neutralization assays ( Figure 1F-1G ), the reciprocal of the serum dilution that resulted in 50% inhibition compared with pseudovirus alone was reported as the 50% neutralization titer (NT50).

In vitro authentic SARS-CoV-2 neutralization assay was performed using Vero-E6 as previously reported (Chi et al., 2020) . Briefly, 1×10 4 /well Vero-E6 cells were seeded in 96-well plates. After culture for 24 hours, the 1:4 serially diluted antibodies (maximum concentration, 5 μg/ml) were mixed with 0.1 MOI (multiplicity of infection) authentic SARS-CoV-2 virus and incubated at 37°C for 30 minutes. This mixture was subsequently added into the cultured Vero-E6 cells. The supernatants were collected after further culture for two days for quantitative reverse transcription PCR and the cells were analyzed by immunofluorescence.

For immunofluorescence, the cells were fixed in 4% paraformaldehyde in PBS for 20 minutes, washed with PBS and permeabilized with 0.1% Triton X-100 in PBS at room temperature. After blocking with 3% BSA, the cells were incubated with anti-N J o u r n a l P r e -p r o o f polyclonal antibody at a dilution of 1:1000 overnight at 4°C and visualized with donkey anti-mouse IgG Alexa Fluor 488 (Thermo Fisher Scientific).

Nuclei were stained with DAPI. Cells were imaged using an Eclipse Ti-S inverted fluorescence microscopy (Nikon).

For quantitative reverse transcription PCR, the viral RNA was extracted from the collected supernatant using Trizol LS (Thermo Fisher Scientific) and used as templates for quantitative PCR analysis by One-Step PrimeScrip RT-PCR Kit (Takara) following the manufacturer's instructions. The primers and probe used were listed in Table S2 . The PCR amplicon by SARS-CoV-2-N-F and SARS-CoV-2-N-R primers was inserted into pUC57 plasmid for standard curve generation. The program of the quantitative reverse transcription PCR was performed using the Mastercycler ep realplex Real-time PCR System (Eppendorf) as followed: 95°C 5 minutes; 40 cycles of 95°C 10 seconds, 50°C 30 seconds, 72°C 30 seconds.

In vitro SARS-CoV-2 pseudovirus ADE assays was performed using Raji cells as previously reported (Jaume et al., 2011) . Briefly, 3×10 4 Raji cells were seeded in each well of 96-well plates coated with 0.01% poly-L-lysine in PBS and cultured for 24 hours. The antibodies were serially diluted 1:2 (maximum concentration, 100 μg/ml) in RPMI 1640 for nine dilutions in total, and were incubated with the SARS-CoV-2 pseudovirus for 30 minutes. The mixture was applied onto the Raji cells and cultured for 60 hours. The measurement of luciferase activity was performed as J o u r n a l P r e -p r o o f described above using a Firefly Luciferase Assay Kit (Promega). The absolute luciferase activity values from all the wells were normalized to the luciferase activity value obtained with 2 μg/ml of antibody XG043 and expressed as the fold change in luciferase activity. Two replicates of XG043 (2 μg/ml) were performed on each plate and the average luciferase activity value of these two replicates was considered as reference (100% relative luciferase activity, the dotted lines in Figure   6A , 6D and 6E, and Figure S6B ). Since many factors (virus concentration, cell concentration, immunofluorescence reading, etc.) vary between different plates or different rounds of experiments, normalization is necessary for comparing the luciferase activity values from different plates. The reason for choosing XG043 as the reference is simply because that XG043 was the first identified to induce ADE in our studies.

For the experiment to block the antibody-dependent viral entry, different concentrations of anti-hCD32 (BD Pharmingen) were incubated with the Raji cells for 30 minutes at 37°C. Then, the mixture of 2 µg/ml antibody XG005 and SARS-CoV-2 pseudovirus was added to the treated Raji cells. The plates were incubated at 37°C for 60 hours before the measurement of luciferase activities as described above.

For in vitro Raji cell-dependent ADE assays using authentic SARS-CoV-2 virus, cultured Raji cells were incubated with the mixture of authentic SARS-CoV-2 virus and monoclonal antibodies (final concentration 4 µg/ml), XG038, XG016 and XG005, J o u r n a l P r e -p r o o f respectively. After 6, 24 or 48 hours incubation, the Raji cells were collected for RNA extraction and quantitative reverse transcription PCR analysis. SARS-CoV-2 Nprotein RNA copy numbers were calculated using a standard curve composed of seven prepared N-protein DNA samples with 10-fold serial dilutions.

The codon optimized wild type cDNA of SARS-CoV-2 receptor-binding domain (RBD) (amino acid 330-530) together with an Avi tag (GLNDIFEAQKIEWHE) was synthesized (GENEWIZ), and cloned into pACgp67 vector with a C-terminal 8×His tag for purification. The SARS-CoV-2 RBD was expressed using the Bac-to-Bac baculovirus system. Extracted bacmid DNA was then transfected into Sf9 cells using Cellfectin II Reagent (Invitrogen). The low-titer viruses were harvested and then amplified to generate high-titer virus stock. The supernatant containing the secreted RBD without glycosylation was harvested 72 hours after infection and the RBD protein was captured by Ni-NTA resin (GE Healthcare) and purified. SDS-PAGE analysis revealed over 95% purity of the purified recombinant protein.

For the site-directed mutagenesis and expression of RBD mutants, SARS-CoV-2 RBD fragment (residue 319-541) and its mutants were synthesized (GenScript), fused with the human IgG1 Fc fragment, and cloned into mammal expression vector pSecTag. The plasmid was transfected into HEK Expi293 cells and incubated at 37°C for four days. Supernatant was harvest for further purification by Protein G resin according to the manufacturer's protocol. Purification of B cells, two-fluorescent-dye labeling of bait protein-binding B cells and single cell sorting experiments were performed as previously described (Escolano et al., 2019; Robbiani et al., 2017; Wang, Q. et al., 2020) . Briefly, PBMCs thawed and washed with RPMI medium were incubated with CD19 MicroBeads (Miltenyi Biotec) for positive selection of B lymphocytes. Sequential incubation at 4°C with human Fc block (BD Biosciences), bait protein-PE/APC (10 μg/ml for RBD, 60 μg/ml for S-ECD), and anti-CD20-PECy7 (BD Biosciences) was performed, followed by the single-cell sorting of CD20-PECy7 + bait protein-PE + bait protein-APC + memory B cells into 96-well plates using a FACSAria II (BD Biosciences). The single-cell sorted B cells were stored at -80°C.

Antibody cloning from the sorted single cells and the production of monoclonal antibodies were done as previously reported (Robbiani et al., 2017; Wang, Q. et al., 2020) . The sequences of primers for the 1 st / 2 nd round of nested PCR were listed in Table S2 . Amplified PCR products from each single cell were loaded onto 2% agarose gel for electrophoresis and purified for Sanger sequencing. All the sequencing result of heavy and kappa/lambda light chains were analyzed by IMGT/V-QUEST (Brochet et al., 2008) and IgBlast (Ye et al., 2013) , and the V(D)J gene segment and CDR3 sequences of each antibody were determined. The selected antibodies were subjected to vector construction and antibody expression as previously described (von Boehmer et al., 2016) .

Relative luciferase activities measured in neutralization or ADE assays or both were used for unsupervised hierarchical clustering analysis with the statistical scripting language R, using log-transformed data, Euclidean correlation coefficients for a distance metric, and ward.D2 clustering. A heatmap and cluster dendrogram tree were created using the Pretty Heatmaps (pheatmap and hclust) R packages.

The detailed results of statistical analysis are shown in the Result and Figure   Legends . The Shapiro-Wilk test and Fisher's F test were employed to check for J o u r n a l P r e -p r o o f normality and homogeneity of variances, respectively, prior to performing the comparison. Student's t test was performed for RBD ELISA ( Figure 1A) , while Wilcoxon Rank Sum test was used for other ELISAs (Figure 1B-1E) and comparisons of ADE AUC ( Figure 7E ) due to their non-normal distribution. In order to determine whether there is a statistically significant difference of the ADE AUC and IC50 values of Cluster-X, -Y, and -Z antibodies, the nonparametric test (Dunn's Kruskal-Wallis multiple comparison) was performed ( Figure 7B and 7C ). Fisher's exact test was performed to assess the statistical significance based on the exact distribution of the frequencies of RBD Group-IV antibodies in three antibody clusters ( Figure 7D ). Table S1 . Detailed information about cloned antibodies with paired heavy and light chains, Related to Figure 2 Variable (V), diversity (D) and joining (J) genes, nucleotide insertion/deletion numbers in the V region, amino acid mutation numbers on the V region, and CDR3 amino acid sequences of cloned immunoglobulin heavy, kappa light and lambda light chains are listed. These antibodies are arranged according to their IGHV genes, with our selected XG001-XG048 antibodies indicated. The amino acid length of IGH CDR3 was between 6 and 26 amino acids, with the highest peak at 14 amino acids and the average around 16 amino acids. There are 28 of IGH CDR3 containing cysteines. The well numbers indicate the corresponding 96-well plate and well numbers for the original sorted single B cells. Different bait proteins were used for sorting: Avi-tagged biotinylated RBD protein (Plate 03-05, 16, 17), chemically biotinylated S-ECD protein (Plate 01, 02), and Avi-tagged biotinylated S-ECD protein

Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity

IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

COVID-19: immunopathology and its implications for therapy

Potent neutralizing antibodies against SARS-CoV-2 identified by highthroughput single-cell sequencing of convalescent patients' B cells

Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity

Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures

Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques

Potent antiviral effect of protoporphyrin IX and verteporfin on SARS-CoV-2 infection

COVID 19 Vaccines: Should we fear ADE?

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The potential danger of suboptimal antibody responses in COVID-19

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcgammaR pathway

An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

A distinct name is needed for the new coronavirus

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Antibody-dependent enhancement of severe dengue disease in humans

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Structure, Function, and Evolution of Coronavirus Spike Proteins

The Impact of Mutations in SARS-CoV-2 Spike on

Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Emergence of RBD mutations in circulating SARS-CoV-2 strains enhancing the structural stability and human ACE2 receptor affinity of the spike protein

IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design

Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Risk of Zika microcephaly correlates with features of maternal antibodies

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Reconstruction of antibody dynamics and infection histories to evaluate dengue risk

A method for identification of HIV gp140 binding memory B cells in human blood

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway

Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold

Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Passive immunotherapy of viral infections: 'super-antibodies' enter the fray

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Pathogenesis of feline infectious peritonitis: nature and development of viremia

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

IgBLAST: an immunoglobulin variable domain sequence analysis tool

Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibodydependent enhancement

Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China

Potently neutralizing and protective human antibodies against SARS-CoV-2

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein